Comparison of the Efficacy and Safety of Direct Oral Anticoagulants and Warfarin in Cirrhotic Patients: A Systematic Review and Meta-Analysis

Overview

Journal Clin Appl Thromb Hemost

Publisher Sage Publications

Specialty Cardiology & Vascular Diseases

Date 2024 Nov 18

PMID 39552309

Authors

Chunwei Cheng

Juan Hua

Liang Xiong

Affiliations

Soon will be listed here.

Abstract

Objective: Currently, there is limited evidence regarding the use of direct oral anticoagulants (DOACs) for patients with liver cirrhosis (LC). We performed a meta-analysis to compare the efficacy and safety of DOACs versus warfarin in this population.

Methods: We searched PubMed, Cochrane Library, Web of Science, Embase and Scopus databases from inception to August 2024. Clinical studies comparing the use of DOACs with warfarin in cirrhotic patients were included. Hazard ratios (HRs) with 95% CIs were estimated by either fixed or random effects models. Primary efficacy outcomes were ischemic stroke/thromboembolism (IS/TE) and all-cause death, the primary safety outcomes were the bleeding risks.

Results: Sixteen studies were included (16 829 individuals). DOACs had similar benefits in preventing IS/TE (HR = 0.87, 95% CI: 0.69-1.10), but DOACs were significantly associated with reduced risk of all-cause death (HR = 0.87, 95% CI: 0.79-0.97). On the other hand, we observed significantly reduced risks of any bleeding (HR = 0.60; 95%CI: 0.37-0.95), major bleeding (HR = 0.72; 95%CI: 0.63-0.82), intracranial hemorrhage (ICH) (HR = 0.47; 95%CI: 0.30-0.73), and gastrointestinal bleeding (GIB) (HR = 0.72, 95% CI: 0.60-0.87) in patients receiving DOACs. Results were consistent in cirrhotic patients with AF. Furthermore, DOACs reduced the incidence of major bleeding (HR = 0.65, 95%CI: 0.55-0.78) and ICH (HR = 0.17, 95%CI: 0.04-0.76) in patients with moderate to severe cirrhosis.

Conclusion: Our study demonstrates that DOACs, compared with warfarin, exerted comparable efficacy and better safety and may represent a safer alternative to warfarin in cirrhotic patients.

References

Xiong J, Xu W, Huang H, Bian J, Wang A, Bai Y . Cirrhosis and risk of stroke: A systematic review and meta-analysis. Atherosclerosis. 2018; 275:296-303. DOI: 10.1016/j.atherosclerosis.2018.06.876. View

Kubitza D, Roth A, Becka M, Alatrach A, Halabi A, Hinrichsen H . Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct Factor Xa inhibitor. Br J Clin Pharmacol. 2013; 76(1):89-98. PMC: 3703231. DOI: 10.1111/bcp.12054. View

Hu T, Li Y, Han W, Maduray K, Chen T, Hao L . Direct Oral Anticoagulants versus Vitamin K Antagonists in Cirrhotic Patients with Atrial Fibrillation: Update of Systematic Review and Meta-Analysis. Am J Cardiovasc Drugs. 2023; 23(6):683-694. DOI: 10.1007/s40256-023-00598-1. View

Nagaoki Y, Aikata H, Daijyo K, Teraoka Y, Shinohara F, Nakamura Y . Efficacy and safety of edoxaban for treatment of portal vein thrombosis following danaparoid sodium in patients with liver cirrhosis. Hepatol Res. 2017; 48(1):51-58. DOI: 10.1111/hepr.12895. View

Munevar Aquite O, Hayes M, Beyene K, Chan A, Schauer C, Wei H . Bleeding risk of oral anticoagulants in liver cirrhosis. N Z Med J. 2022; 135(1563):52-61. DOI: 10.26635/6965.5832. View

Oldham M, Palkimas S, Hedrick A . Safety and Efficacy of Direct Oral Anticoagulants in Patients With Moderate to Severe Cirrhosis. Ann Pharmacother. 2021; 56(7):782-790. DOI: 10.1177/10600280211047433. View

Sasso R, Rockey D . Anticoagulation Therapy in Patients with Liver Cirrhosis is Associated With an Increased Risk of Variceal Hemorrhage. Am J Med. 2019; 132(6):758-766. DOI: 10.1016/j.amjmed.2019.01.006. View

Kuo L, Chao T, Liu C, Lin Y, Chang S, Lo L . Liver Cirrhosis in Patients With Atrial Fibrillation: Would Oral Anticoagulation Have a Net Clinical Benefit for Stroke Prevention?. J Am Heart Assoc. 2017; 6(6). PMC: 5669162. DOI: 10.1161/JAHA.116.005307. View

Simon T, Singer D, Zhang Y, Mastrorilli J, Cervone A, DiCesare E . Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients With Cirrhosis and Atrial Fibrillation : A Nationwide Cohort Study. Ann Intern Med. 2024; 177(8):1028-1038. PMC: 11671173. DOI: 10.7326/M23-3067. View

10.

Fu Y, Zhu W, Zhou Y, Chen H, Yan L, He W . Non-vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Patients with Atrial Fibrillation and Liver Disease: A Meta-Analysis and Systematic Review. Am J Cardiovasc Drugs. 2019; 20(2):139-147. DOI: 10.1007/s40256-019-00369-x. View

11.

Lawal O, Aronow H, Hume A, Shobayo F, Matson K, Barbour M . Venous thromboembolism, chronic liver disease and anticoagulant choice: effectiveness and safety of direct oral anticoagulants versus warfarin. Res Pract Thromb Haemost. 2024; 8(1):102293. PMC: 10805675. DOI: 10.1016/j.rpth.2023.102293. View

12.

Lisman T, Porte R . Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood. 2010; 116(6):878-85. DOI: 10.1182/blood-2010-02-261891. View

13.

Douros A, Cui Y, Platt R, Filion K, Sebastiani G, Renoux C . Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: A multinational cohort study. Thromb Res. 2024; 237:71-78. DOI: 10.1016/j.thromres.2024.03.024. View

14.

Douros A, Cui Y, Platt R, Filion K, Sebastiani G, Renoux C . Utilization and long-term persistence of direct oral anticoagulants among patients with nonvalvular atrial fibrillation and liver disease. Br J Clin Pharmacol. 2021; 88(3):994-1009. DOI: 10.1111/bcp.15046. View

15.

Flores B, Trivedi H, Robson S, Bonder A . Hemostasis, bleeding and thrombosis in liver disease. J Transl Sci. 2018; 3(3). PMC: 6136435. DOI: 10.15761/JTS.1000182. View

16.

Zhang X, Qi X, Yoshida E, Mendez-Sanchez N, Hou F, Deng H . Ischemic stroke in liver cirrhosis: epidemiology, risk factors, and in-hospital outcomes. Eur J Gastroenterol Hepatol. 2017; 30(2):233-240. DOI: 10.1097/MEG.0000000000001011. View

17.

Lee H, Chan Y, Chang S, Tu H, Chen S, Yeh Y . Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2019; 8(5):e011112. PMC: 6474939. DOI: 10.1161/JAHA.118.011112. View

18.

Simon T, Schneeweiss S, Singer D, Sreedhara S, Lin K . Prescribing Trends of Oral Anticoagulants in US Patients With Cirrhosis and Nonvalvular Atrial Fibrillation. J Am Heart Assoc. 2023; 12(3):e026863. PMC: 9973619. DOI: 10.1161/JAHA.122.026863. View

19.

Kearon C, Akl E, Ornelas J, Blaivas A, Jimenez D, Bounameaux H . Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest. 2016; 149(2):315-352. DOI: 10.1016/j.chest.2015.11.026. View

20.

Hoolwerf E, Kraaijpoel N, Buller H, van Es N . Direct oral anticoagulants in patients with liver cirrhosis: A systematic review. Thromb Res. 2018; 170:102-108. DOI: 10.1016/j.thromres.2018.08.011. View